Switch theme
Sign up to access all valuation multiples
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types.
1996
861
LTM Revenue $191M
LTM EBITDA -$10.6M
$524M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oxford BioMedica has a last 12-month revenue (LTM) of $191M and a last 12-month EBITDA of -$10.6M.
In the most recent fiscal year, Oxford BioMedica achieved revenue of $173M and an EBITDA of -$19.2M.
Oxford BioMedica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oxford BioMedica valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $191M | XXX | $173M | XXX | XXX | XXX |
| Gross Profit | $85.3M | XXX | $71.2M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | -$10.6M | XXX | -$19.2M | XXX | XXX | XXX |
| EBITDA Margin | -6% | XXX | -11% | XXX | XXX | XXX |
| EBIT | -$41.8M | XXX | -$58.4M | XXX | XXX | XXX |
| EBIT Margin | -22% | XXX | -34% | XXX | XXX | XXX |
| Net Profit | -$52.2M | XXX | -$58.0M | XXX | XXX | XXX |
| Net Margin | -27% | XXX | -34% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Oxford BioMedica's stock price is GBP 3 (or $4).
Oxford BioMedica has current market cap of GBP 342M (or $460M), and EV of GBP 390M (or $524M).
See Oxford BioMedica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $524M | $460M | XXX | XXX | XXX | XXX | $-0.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Oxford BioMedica has market cap of $460M and EV of $524M.
Oxford BioMedica's trades at 3.0x EV/Revenue multiple, and -27.2x EV/EBITDA.
Equity research analysts estimate Oxford BioMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oxford BioMedica has a P/E ratio of -8.8x.
See valuation multiples for Oxford BioMedica and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $460M | XXX | $460M | XXX | XXX | XXX |
| EV (current) | $524M | XXX | $524M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | -49.3x | XXX | -27.2x | XXX | XXX | XXX |
| EV/EBIT | -12.6x | XXX | -9.0x | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.8x | XXX | -7.9x | XXX | XXX | XXX |
| EV/FCF | -11.5x | XXX | -6.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOxford BioMedica's last 12 month revenue growth is 27%
Oxford BioMedica's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Oxford BioMedica's rule of 40 is -139% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oxford BioMedica's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oxford BioMedica and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Margin | -6% | XXX | -11% | XXX | XXX | XXX |
| EBITDA Growth | -260% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -139% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 75% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oxford BioMedica acquired XXX companies to date.
Last acquisition by Oxford BioMedica was XXXXXXXX, XXXXX XXXXX XXXXXX . Oxford BioMedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Oxford BioMedica founded? | Oxford BioMedica was founded in 1996. |
| Where is Oxford BioMedica headquartered? | Oxford BioMedica is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Oxford BioMedica have? | As of today, Oxford BioMedica has 861 employees. |
| Who is the CEO of Oxford BioMedica? | Oxford BioMedica's CEO is Dr. Frank Mathias. |
| Is Oxford BioMedica publicy listed? | Yes, Oxford BioMedica is a public company listed on LON. |
| What is the stock symbol of Oxford BioMedica? | Oxford BioMedica trades under OXB ticker. |
| When did Oxford BioMedica go public? | Oxford BioMedica went public in 2001. |
| Who are competitors of Oxford BioMedica? | Similar companies to Oxford BioMedica include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Oxford BioMedica? | Oxford BioMedica's current market cap is $460M |
| What is the current revenue of Oxford BioMedica? | Oxford BioMedica's last 12 months revenue is $191M. |
| What is the current revenue growth of Oxford BioMedica? | Oxford BioMedica revenue growth (NTM/LTM) is 27%. |
| What is the current EV/Revenue multiple of Oxford BioMedica? | Current revenue multiple of Oxford BioMedica is 2.7x. |
| Is Oxford BioMedica profitable? | Yes, Oxford BioMedica is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Oxford BioMedica? | Oxford BioMedica's last 12 months EBITDA is -$10.6M. |
| What is Oxford BioMedica's EBITDA margin? | Oxford BioMedica's last 12 months EBITDA margin is -6%. |
| What is the current EV/EBITDA multiple of Oxford BioMedica? | Current EBITDA multiple of Oxford BioMedica is -49.3x. |
| What is the current FCF of Oxford BioMedica? | Oxford BioMedica's last 12 months FCF is -$45.7M. |
| What is Oxford BioMedica's FCF margin? | Oxford BioMedica's last 12 months FCF margin is -24%. |
| What is the current EV/FCF multiple of Oxford BioMedica? | Current FCF multiple of Oxford BioMedica is -11.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
